Beini Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beini Sun has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Tongsheng Chen
MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, College of Biophotonics, School of Optoelectronic Science and Engineering, South China Normal University, Guangzhou 510631, China
3 shared publications - Xiaoping Wang
Department of Pain Management The First Affiliated Hospital of Jinan University Guangzhou China
3 shared publications - Chuan Peng
MOE Key Laboratory of Laser Life Science & Guangdong Provincial Key Laboratory of Laser Life Science College of Biophotonics South China Normal University Guangzhou China
1 shared publication - Guihao Wu
Department of Pain Management, The First Affiliated Hospital of Jinan University, Guangzhou, China
1 shared publication - Han Sun
The Department of Biomedical Engineering, Institute of Advanced Clinical Medicine, Peking University, Beijing 100191, P. R. China
1 shared publication - Hongce Chen
MOE Key Laboratory of Laser Life Science & Guangdong Provincial Key Laboratory of Laser Life Science, College of Biophotonics, School of Optoelectronic Science and Engineering, South China Normal University, Guangzhou 510631, China
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70878
Live‐cell FRET imaging‐based efficacy prediction of EGFR‐TKIs in EGFR L858R‐mutant NSCLC
Objectives: Functional assays can assist individualised selection of treatment regimens by evaluating the ex vivo response of tumour cells to anticancer therapeutics. However, the two major strategies used to assess responses to targeted drugs, target‐based profiling and phenotypic profiling, have inherent limitations. Target‐based profiling does not directly capture downstream cell‐fate outcomes, whereas phenotypic profiling provides limited mechanistic information on drug action. Methods: Live‐cell fluorescence resonance energy transfer (FRET) microscopy was used to integrate the interaction between EGFR L858R and GRB2 with cellular phenotypic features, thereby predicting the efficacy of EGFR‐tyrosine kinase inhibitors (TKIs) at the single‐cell level. Results: The target‐based drug score ( T ‐score), derived from the interaction between EGFR L858R and GRB2 in living cells co‐expressing CFP‐EGFR L858R and YFP‐GRB2, enabled evaluation of the on‐target activity of EGFR‐TKIs against EGFR L858R . The phenotype drug score ( P ‐score), constructed from cellular phenotype features, characterised the phenotypic responses induced by EGFR‐TKIs. The TP ‐score, integrating the T ‐ and P ‐scores, accurately predicted the efficacy of EGFR‐TKIs. In living H3255 cells, the TP ‐score of osimertinib (OSI) was higher than that of gefitinib (GEF). Notably, in H3255 cell‐derived xenograft (CDX) mouse models, OSI showed superior in vivo antitumour efficacy compared with GEF. Furthermore, live‐cell TP scoring revealed that primary tumour cells from a patient with NSCLC did not respond to OSI, a finding consistent with the absence of actionable EGFR mutations in this patient. Conclusions: This study demonstrates the clinical feasibility of predicting EGFR‐TKI efficacy by integrating EGFR L858R ‐GRB2 interactions with cellular phenotypic features in single living cells.
- 24 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70878
Open AccessLive‐cell FRET imaging‐based efficacy prediction of EGFR‐TKIs in EGFR L858R‐mutant NSCLC
Objectives: Functional assays can assist individualised selection of treatment regimens by evaluating the ex vivo response of tumour cells to anticancer therapeutics. However, the two major strategies used to assess responses to targeted drugs, target‐based profiling and phenotypic profiling, have inherent limitations. Target‐based profiling does not directly capture downstream cell‐fate outcomes, whereas phenotypic profiling provides limited mechanistic information on drug action. Methods: Live‐cell fluorescence resonance energy transfer (FRET) microscopy was used to integrate the interaction between EGFR L858R and GRB2 with cellular phenotypic features, thereby predicting the efficacy of EGFR‐tyrosine kinase inhibitors (TKIs) at the single‐cell level. Results: The target‐based drug score ( T ‐score), derived from the interaction between EGFR L858R and GRB2 in living cells co‐expressing CFP‐EGFR L858R and YFP‐GRB2, enabled evaluation of the on‐target activity of EGFR‐TKIs against EGFR L858R . The phenotype drug score ( P ‐score), constructed from cellular phenotype features, characterised the phenotypic responses induced by EGFR‐TKIs. The TP ‐score, integrating the T ‐ and P ‐scores, accurately predicted the efficacy of EGFR‐TKIs. In living H3255 cells, the TP ‐score of osimertinib (OSI) was higher than that of gefitinib (GEF). Notably, in H3255 cell‐derived xenograft (CDX) mouse models, OSI showed superior in vivo antitumour efficacy compared with GEF. Furthermore, live‐cell TP scoring revealed that primary tumour cells from a patient with NSCLC did not respond to OSI, a finding consistent with the absence of actionable EGFR mutations in this patient. Conclusions: This study demonstrates the clinical feasibility of predicting EGFR‐TKI efficacy by integrating EGFR L858R ‐GRB2 interactions with cellular phenotypic features in single living cells.
- 1 June 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (19) , 5219-5233
PINK1/Parkin‐based live‐cell quantitative FRET imaging for mitophagy drug screening
PINK1 (PTEN‐induced kinase 1) and Parkin (parkin RBR E3 ubiquitin protein) ligase are important regulators for cells to maintain mitochondrial number and functional homeostasis. Here, we established a PINK1/Parkin‐based mitophagy drug evaluation method using quantitative Förster resonance energy transfer (FRET) imaging in living cells. A stable model of carbonyl cyanide 3‐chlorophenylhydrazone (CCCP)‐induced mitophagy was established, verified by increased colocalization of mitochondria with LC3 aggregates, decreased mitochondrial membrane potential (MMP), and increased intracellular reactive oxygen species (ROS) level. Next, by silencing PINK1 and overexpressing LC3 proteins in MCF‐7 cells, it was verified that PINK1 and Parkin significantly promoted CCCP‐induced mitophagy, in which CCCP promoted the direct interaction of PINK1 and Parkin. Quantitative FRET imaging analysis for the cells coexpressing CFP‐PINK1 and YFP‐Parkin was used to assess the action of five drugs [3‐methyladenine (3‐MA), CCCP, doxorubicin hydrochloride (DOX), metformin (Met), resveratrol (RSV)] on the interaction between PINK1 and Parkin. After 6 h of treatment with these drugs, the CCCP, DOX, Met, and RSV groups showed significantly higher maximum donor‐centric FRET efficiency (EDmax) than the control group, suggesting that these four drugs promoted the direct interaction between PINK1 and Parkin. While the 3‐MA group showed similar EDmax to the control group, suggesting that 3‐MA did not promote direct interaction between PINK1 and Parkin. We also performed these experiments in HeLa cells and obtained the same results, further demonstrating that the PINK1/Parkin‐based quantitative FRET drug screening method is a potential tool for mitophagy drug screening in living cells.
- 1 June 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (19) , 5219-5233
PINK1/Parkin‐based live‐cell quantitative FRET imaging for mitophagy drug screening
PINK1 (PTEN‐induced kinase 1) and Parkin (parkin RBR E3 ubiquitin protein) ligase are important regulators for cells to maintain mitochondrial number and functional homeostasis. Here, we established a PINK1/Parkin‐based mitophagy drug evaluation method using quantitative Förster resonance energy transfer (FRET) imaging in living cells. A stable model of carbonyl cyanide 3‐chlorophenylhydrazone (CCCP)‐induced mitophagy was established, verified by increased colocalization of mitochondria with LC3 aggregates, decreased mitochondrial membrane potential (MMP), and increased intracellular reactive oxygen species (ROS) level. Next, by silencing PINK1 and overexpressing LC3 proteins in MCF‐7 cells, it was verified that PINK1 and Parkin significantly promoted CCCP‐induced mitophagy, in which CCCP promoted the direct interaction of PINK1 and Parkin. Quantitative FRET imaging analysis for the cells coexpressing CFP‐PINK1 and YFP‐Parkin was used to assess the action of five drugs [3‐methyladenine (3‐MA), CCCP, doxorubicin hydrochloride (DOX), metformin (Met), resveratrol (RSV)] on the interaction between PINK1 and Parkin. After 6 h of treatment with these drugs, the CCCP, DOX, Met, and RSV groups showed significantly higher maximum donor‐centric FRET efficiency (EDmax) than the control group, suggesting that these four drugs promoted the direct interaction between PINK1 and Parkin. While the 3‐MA group showed similar EDmax to the control group, suggesting that 3‐MA did not promote direct interaction between PINK1 and Parkin. We also performed these experiments in HeLa cells and obtained the same results, further demonstrating that the PINK1/Parkin‐based quantitative FRET drug screening method is a potential tool for mitophagy drug screening in living cells.
- Open Access
- 22 November 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-9
Bak instead of Bax plays a key role in metformin-induced apoptosis s in HCT116 cells
Metformin (Met) exhibits anticancer ability in various cancer cell lines. This report aims to explore the exact molecular mechanism of Met-induced apoptosis in HCT116 cells, a human colorectal cancer cell line. Met-induced reactive oxygen species (ROS) increase and ROS-dependent cell death accompanied by plasma membrane blistering, mitochondrial swelling, loss of mitochondrial membrane potential, and release of cytochrome c. Western blotting analysis showed that Met upregulated Bak expression but downregulated Bax expression. Most importantly, silencing Bak instead of Bax inhibited Met-induced loss of mitochondrial membrane potential, indicating the key role of Bak in Met-induced apoptosis. Live-cell fluorescence resonance energy transfer (FRET) analysis showed that Met unlocked the binding of Mcl-1 to Bak, and enhanced the binding of Bim to Bak and subsequent Bak homo-oligomerization. Western blotting analysis showed that Met enhanced AMPK phosphorylation and Bim expression, and compound C, an inhibitor of AMPK, inhibited Met-induced Bim upregulation. Although Met increased the expression of Bcl-xL, overexpression of Bcl-xL did not prevent Met-induced apoptosis. In summary, our data demonstrate for the first time that Met promotes ROS-dependent apoptosis by regulating the Mcl-1-Bim-Bak axis.
- 22 November 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-9
Open AccessBak instead of Bax plays a key role in metformin-induced apoptosis s in HCT116 cells
Metformin (Met) exhibits anticancer ability in various cancer cell lines. This report aims to explore the exact molecular mechanism of Met-induced apoptosis in HCT116 cells, a human colorectal cancer cell line. Met-induced reactive oxygen species (ROS) increase and ROS-dependent cell death accompanied by plasma membrane blistering, mitochondrial swelling, loss of mitochondrial membrane potential, and release of cytochrome c. Western blotting analysis showed that Met upregulated Bak expression but downregulated Bax expression. Most importantly, silencing Bak instead of Bax inhibited Met-induced loss of mitochondrial membrane potential, indicating the key role of Bak in Met-induced apoptosis. Live-cell fluorescence resonance energy transfer (FRET) analysis showed that Met unlocked the binding of Mcl-1 to Bak, and enhanced the binding of Bim to Bak and subsequent Bak homo-oligomerization. Western blotting analysis showed that Met enhanced AMPK phosphorylation and Bim expression, and compound C, an inhibitor of AMPK, inhibited Met-induced Bim upregulation. Although Met increased the expression of Bcl-xL, overexpression of Bcl-xL did not prevent Met-induced apoptosis. In summary, our data demonstrate for the first time that Met promotes ROS-dependent apoptosis by regulating the Mcl-1-Bim-Bak axis.